A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
Completed
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants with treatment-resistant depression (TRD).
Gender:
ALL
Ages:
Between 20 years and 64 years
Trial Updated:
04/25/2025
Locations: Not set, Memphis, Tennessee
Conditions: Treatment Resistant Depressive Disorder
Low-Dose Ketamine Infusion During Burn Wound Care
Recruiting
The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Regional One Health, Memphis, Tennessee
Conditions: Burn, Pain, Dissociation, Opioid
IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D
Completed
The general objective of this study is to determine whether intranasal ketamine should be incorporated into formulary as an option to treat pain during minor procedures in the pediatric emergency department.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
03/23/2017
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Abscess, Pain